Ionis Pharmaceuticals (MEX:IONS) LT-Debt-to-Total-Asset: 0.47 (As of Mar. 2026)


MEX:IONS Ionis Pharmaceuticals Inc MEX:IONS
65 GF Score
Price MXN1,150.00
GF Value MXN782.91
! 8 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals LT-Debt-to-Total-Asset?

Ionis Pharmaceuticals MEX:IONS 65 LT-Debt-to-Total-Asset is 0.47 as of Mar. 2026. GuruFocus rates MEX:IONS with a GF Score™ of 65/100 and a GF Value™ of MXN782.91. The stock has 8 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Ionis Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.47.

Ionis Pharmaceuticals's long-term debt to total assets ratio declined from Mar. 2025 (0.50) to Mar. 2026 (0.47). It may suggest that Ionis Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

Ionis Pharmaceuticals  (MEX:IONS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Ionis Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Ionis Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals LT-Debt-to-Total-Asset Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 0.54 0.47 0.47 0.46

Ionis Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.27 0.28 0.46 0.47
MEX:IONS
65GF Score
Ionis Pharmaceuticals Inc MEX:IONS
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Ionis Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=28986.044/63449.134
=0.46

Ionis Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=29004.768/62212.256
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.47 mean?
Ionis Pharmaceuticals (MEX:IONS) has a LT-Debt-to-Total-Asset of 0.47 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' LT-Debt-to-Total-Asset too high?
Ionis Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.47. Overall, Ionis Pharmaceuticals has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' LT-Debt-to-Total-Asset compare to EXEL and BBIO?
Ionis Pharmaceuticals' LT-Debt-to-Total-Asset of 0.47 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current LT-Debt-to-Total-Asset of 0.47. The stock's GF Value™ is MXN782.91, compared to a current price of MXN1,150.00 — trading 46.9% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.47. Ionis Pharmaceuticals' overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current LT-Debt-to-Total-Asset is 0.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,150.00 is trading 46.9% above its estimated GF Value™ of MXN782.91.

Key valuation signals for MEX:IONS:

  • LT-Debt-to-Total-Asset: 0.47
  • GF Value™: MXN782.91 vs. price of MXN1,150.00 (46.9% above fair value)
  • GF Score™: 65/100 with 8 warning signs

No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
65GF Score

Get the complete analysis for MEX:IONS

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,150.00
Price
MXN782.91
GF Value